Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroendocrine Tumor (NET) Clear all
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Interventions
Structured Lipid Medical Food
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
Interventions
Everolimus, Placebo, Best suportive care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
Interventions
Everolimus 10 mg, Octreotide Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced May 22, 2026, 2:47 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumor
Interventions
90Y-DOTA-TOC, 68Ga-DOTA-TOC
Drug
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Neuroendocrine Tumors of Pancreatic Origin
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
24
States / cities
Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced May 22, 2026, 2:47 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Octreotide LAR, Lanreotide ATG
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Interventions
Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
Drug · Combination Product
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
Interventions
MK-0646
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
Lanreotide, Pembrolizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Durham, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced May 22, 2026, 2:47 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
Interventions
Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
Drug · Other
Lead sponsor
Chandrikha Chandrasekhara
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced May 22, 2026, 2:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
Interventions
Surufatinib
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions
PEN-221
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Tumor
Interventions
Quarfloxin
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • Fort Collins, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor
Interventions
RYZ401
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
4
States / cities
Iowa City, Iowa • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 2:47 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
18F-mFBG
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced May 22, 2026, 2:47 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions
177Lu-DOTATOC
Drug
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastro-Enteropancreatic Neuroendocrine Tumor
Interventions
Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced May 22, 2026, 2:47 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions
CRN09682
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Phoenix, Arizona • Duarte, California • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 2:47 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 22, 2026, 2:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Telotristat (Low-Dose), Telotristat (High-Dose)
Drug
Lead sponsor
Lowell Anthony, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced May 22, 2026, 2:47 AM EDT